Homepage News

January 5, 2019. Sera Prognostics Receives New York State Approval for PreTRM® Testing

Salt Lake City, Dec. 12, 2018 — Sera Prognostics, Inc., a women’s health company, announced today that the New York State Department of Health has issued a clinical laboratory permit for Sera to perform PreTRM® testing for pregnant women in the state of New York. The lab approval was based on the results of an on-site inspection and rigorous evaluation process.  With this approval, Sera can now commercialize the PreTRM® test in New York, a very important health care market.

New York’s Clinical Laboratory Reference System (CLRS) provides guidelines, quality control standards and procedures to be used by permit-holding clinical facilities that provide laboratory services to healthcare providers in the state.  In recognition of the fact that CLRS has requirements that are equal to or more stringent than the Clinical Laboratory Improvement Amendments of 1988 (CLIA), the program was granted exempt status by the federal Centers for Medicare and Medicaid Services (CMS) in 1995.

With New York State approval of Sera’s laboratory and PreTRM® test (https://www.wadsworth.org/regulatory/clep/approved-labs), Sera is permitted to provide its innovative laboratory testing services for intended use by pregnant women in all states nationwide.

“Sera is the only company to rigorously develop, validate, and receive state regulatory approval across the entire U.S. for its innovative PreTRM blood test.  The PreTRM test objectively assesses the individual risk of premature birth by analyzing blood drawn early in pregnancy,” stated Greg C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics. “The approval by New York State is strong recognition of the quality and clinical utility of Sera’s PreTRM test.  Sera is proud to be able to provide PreTRM’s important information to doctors and patients in New York State, to better inform earlier proactive decision-making.”

Preterm birth affects approximately 1 in 10 pregnancies in the US1 and can result in both short- and long-term complications.  The annual costs in the US healthcare system of managing prematurity and its complications were estimated at $31.5B2 in 2015.

About Preterm Birth
According to the March of Dimes, globally preterm birth affects 15 million infants each year, with 1 million deaths occurring from prematurity. Of nearly 4 million babies born annually in the U.S., approximately one in ten is born prematurely.1Preterm birth is defined as any birth before 37 weeks gestation and is the leading cause of illness and death in newborns. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children.

About the PreTRM® Test
The PreTRM® test is the only broadly clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test is ordered by a medical professional. For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.
Sera Prognostics is a global leader in high-value women’s health diagnostics, delivering pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® test is available nationwide through the Company’s collaboration with LabCorp. PreTRM is the only broadly clinically-validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

1 http://www.marchofdimes.org/mission/prematurity-reportcard.aspx
2 Caughey et al, Am J Perinatol Rep 2016;6:e407-e416

More Info
January 5, 2019. Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test

 – TREETOP Study will Explore Enhancements to Sera’s Validated PreTRM® Test –

Salt Lake City, Nov. 27, 2018 — Sera Prognostics, Inc., a women’s health company, announced today that it has completed enrollment of 5,009 women into its prospective real-time study, “A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP).”  TREETOP enrollment was conducted in 17 centers across the US. The study is designed to prospectively evaluate Sera’s clinically validated PreTRM® test under real-time clinical testing conditions. In addition, data from TREETOP will enable Sera to explore enhancements that will provide additional important insights about a woman’s pregnancy that could better inform expectant mothers and their physicians when making clinical and lifestyle decisions.

Preterm birth affects approximately 1 in 10 pregnancies in the US1 and can result in both short- and long-term complications.  The annual costs in the US healthcare system of managing prematurity and its complications were estimated at $31.5B2 in 2015.

“Patients matter: mother, child and family. Sera is committed to what is best for patients by applying rigor and care in developing and validating its tests for clinical use,” said Gregory C. Critchfield, M.D., M. S., chairman and chief executive officer of Sera Prognostics. “We thank our excellent collaborators at each of the TREETOP sites for their dedication in joining with us to advance this research. The data from this study will further support achieving Sera’s vision: to improve the health and well-being of mothers and newborns world-wide.”

The final results of the TREETOP trial are expected to be completed during 2019, as deliveries occur from the patients now enrolled in the study.  For more information, please visit (https://clinicaltrials.gov/ct2/show/NCT02787213).

About TREETOP
The TREETOP study is a multicenter, prospective, real-time observational study to assess spontaneous preterm birth risk. The study involves leading investigators in 17 clinical sites that represent the broad diversity of patients across the U.S. Blood samples were prospectively collected from pregnant women between 17 and 22 weeks of gestation. 

The TREETOP study design follows authoritative National Academy of Medicine guidelines (Evolution of Translational Omics: Lessons Learned and the Path Forward, 2012) for validating tests that combine multiple biomarkers into predictions suitable for clinical use. The proper validation of such tests starts with a careful definition of intended use patients (the clinical characteristics of which must well-defined and known prior to applying such a test). Discovery, verification (confirmation) and validation activities take place on three separate (independent) specimen sets of such patients. Carefully following these guidelines improves the quality and defines the applicability of these tests – essentially eliminating the risk that the performance of a test is due to chance and not representative of what would occur in actual clinical practice. A final desirable step in the Academy’s guidance is to validate prospectively the performance of a test in a set of patients entirely different than those studied previously.

The results from TREETOP are intended to help physicians and women to make better informed decisions by identifying patients at risk for adverse outcomes, and by more deeply characterizing the course of pregnancy, enabling more proactive management than is currently possible.

About Preterm Birth
According to the March of Dimes, globally preterm birth affects 15 million infants each year, with 1 million deaths occurring from prematurity. Of nearly 4 million babies born annually in the U.S., approximately one in ten is born prematurely.1Preterm birth is defined as any birth before 37 weeks gestation and is the leading cause of illness and death in newborns. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children.

About the PreTRM® Test
The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test is ordered by a medical professional. For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.
Sera Prognostics is a global leader in high-value women’s health diagnostics, delivering pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® test is available nationwide through the Company’s collaboration with LabCorp. PreTRM is the first and only broadly clinically-validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

1 http://www.marchofdimes.org/mission/prematurity-reportcard.aspx
2 Caughey et al, Am J Perinatol Rep 2016;6:e407-e416

More Info
August 1, 2018. Intermountain Health and Christiana Care Health System Begin Enrollment on Two Landmark Preterm Birth Studies with PreTRM® Test

— PREVENT PRETERM AND AVERT PRETERM TRIAL will assess impact of interventions based on early risk identification to prolong pregnancy and reduce the rate of preterm birth–

Salt Lake City, July 1, 2018 – Sera Prognostics®, The Pregnancy Company™, announces the recent launch of two new preterm birth studies using the PreTRM® test to identify high-risk mothers for intervention care.  These studies are being run by Intermountain Healthcare in Utah and Christiana Care Health System in Delaware.  Both intervention studies will use Sera’s PreTRM® test to identify women at high risk of early delivery that will receive proactive interventions with the goal of reducing the rate of premature delivery and improving newborn health.

In May, Intermountain Healthcare launched PREVENT PTB, a first of its kind study involving up to 10,000 women that will use the PreTRM® test to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery.  D. Ware Branch, MD, medical director of Intermountain Healthcare’s Women and Newborns Clinical Program, is principal investigator of the study.  For more information on the PREVENT PTB study, please visit: HealthClinicalTrials.gov Identifier: NCT03530332.

In June, Christiana Care Health System launched the AVERT PRETERM TRIAL. This study will enroll nearly 3,000 women, comparing a test/treat arm, where high-PreTRM® risk patients receive intensive interventions, to a historical control arm whose patients did not receive PreTRM® testing, but received usual standard of care treatment.   The principal investigator for the study is Matthew Hoffman, M.D., MPH, FACOG, Marie E. Pinizzotto, M.D., Endowed Chair of Obstetrics and Gynecology at Christiana Care Health System in Wilmington, Delaware. For more information on the AVERT study, please visit:

HealthClinicalTrials.gov Identifier: NCT03151330.

“We are pleased to support these two outstanding organizations as they advance clinical research to show the benefits of early identification and proactive intervention in reducing preterm birth rates and improving the health of babies,” said Gregory C. Critchfield, MD, MS, chair and CEO of Sera Prognostics. “By identifying more pregnancies where earlier, more proactive intervention is beneficial, society, families and, most importantly newborn infants, have the potential for better outcomes and lower healthcare costs.”

These two intervention studies will create data to support future insurance coverage and physician adoption for Sera’s PreTRM® test.

About the PreTRM® Test

The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test is ordered by a medical professional. For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.

Sera Prognostics is a global leader in high value women’s health diagnostics, delivering pivotal information to physicians to improve health and improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera’s PreTRM® test is available nationwide through the Company’s collaboration with LabCorp. PreTRM is the first and only broadly clinically-validated blood test that is used early in pregnancy to accurately predict the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, the Bill & Melinda Gates Foundation, and LabCorp. Sera is collaborating with the Gates Foundation to translate its discoveries into technologies well suited for low and middle-income countries in its journey to improve maternal and infant health globally. Two prospective intervention studies are underway to demonstrate the impact of proactive treatment to reduce the rate of preterm birth when women are identified at high risk of prematurity with the PreTRM test.  Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

 

More Info
May 29, 2018. Intermountain Healthcare Launches New Study to Determine Benefit of Proactive Interventions in Reducing Premature Births

Prevent PTB Study will Incorporate New PreTRM Blood Test to Identify Women at Risk

INTERMOUNTAIN MEDICAL NEWS – May 29, 2018.

Intermountain Healthcare is launching the first study of its kind involving up to 10,000 women that will use a new test to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery.

For the Prevent PTB study, half of the study participants will undergo normal medical screening to determine their risk of preterm birth. The other half will give a blood sample for Sera Prognostics’ validated PreTRM test.

Previous research of more than 5,500 women found the PreTRM test accurately identifies pregnant women at high risk of preterm birth, even if they have no previous history or other signs of the condition, such as a shortened cervix.

“This is the first time we’re able to use a blood test to identify the women at highest risk and start to intervene to prevent the preterm birth,” said D. Ware Branch, MD, medical director of Intermountain Healthcare’s Women and Newborns Clinical Program, who is principal investigator of the study.

Pregnant women will be recruited for the Prevent PTB study at five Intermountain hospitals: Intermountain Medical Center in Murray, Dixie Regional Medical Center in St. George, LDS Hospital in Salt Lake City, Utah Valley Medical Center in Provo, and McKay-Dee Hospital in Ogden. Salt Lake City-based Sera Prognostics is funding the research.

“We are pleased to see Intermountain leading clinical research with this important study. The Prevent PTB study is designed to show the benefits of early identification and proactive intervention in reducing preterm birth rates and improving the health of babies,” said Gregory C. Critchfield, MD, MS, chair and CEO of Sera Prognostics. “By identifying more pregnancies where earlier, more proactive intervention is beneficial, society, families and, most importantly newborn infants, have the potential for better outcomes and lower healthcare costs.”

Preterm birth is the leading cause of newborn death — and it can afflict babies who survive for the rest of their lives with blindness, deafness, cerebral palsy, developmental delays, and learning disabilities.  Other long-term complications include chronic respiratory illness, seizures, and vision and hearing loss. Lifelong care for children with such conditions is expensive.

A March of Dimes national report found that preterm birth – defined as birth before 37 weeks of the normal 40 weeks – affects 15 million infants worldwide each year and causes 1 million deaths. Of almost 4 million babies delivered annually in the U.S., approximately 11 percent of births are preterm.The rate in Utah is slightly less.

“The biggest challenge we have in trying to treat preterm birth is we don’t know who’s going to have it,”said researcher Sean Esplin, MD, a maternal-fetal specialist at Intermountain Medical Center and director of research for women and newborn services for Intermountain Healthcare, who is a scientific founder of Sera Prognostics. “Out of every 100 pregnant women who come to my office, I know 10 of them will deliver early. But I don’t know which 10 to focus on, except for a few with a previous preterm birth, shortened cervix, or other risk factors. Otherwise, I have to wait until they come in with symptoms, and by then, it’s often too late to stop it.”

That’s why Intermountain Healthcare is using the PreTRM blood test to assess risk earlier. Previous published research shows that when blood is tested as early as 19 or 20 weeks gestation, PreTRM accurately predicts a woman’s chance of having a preterm birth by measuring and analyzing a pattern of proteins in the blood, focusing on two with high predictive performance.

“Of all the women who are pregnant, our current clinical methods identify fewer than half of those who eventually will give birth before 37 weeks,” said Dr. Branch. “We hope to show this test will identify a goodly proportion of the remaining patients to determine whether doing the test can enable interventions that prevent preterm births and/or improve neonatal outcomes among those who are born prematurely.”

The new Prevent PTB study will use such treatments on women who are carrying one baby and lack common symptoms, but are identified by the PreTRM test as being at high risk of preterm birth.

Women with a history of preterm birth, who are under age 18, or more than 21 weeks pregnant aren’t eligible for the study. Pregnant women enrolled in the study will be randomly assigned to the experimental group or a control group.

Women in the experimental group will receive the PreTRM blood test, and those found to be at high risk of preterm birth will undergo the study’s early, pre-emptive treatments to determine if they can reduce the number of preterm births and newborn deaths, and shorten hospital stays for premature babies.

Medical interventions used to reduce the likelihood of preterm birth or to lengthen gestation include injected or intravaginal progesterone hormone, which alone can reduce the risk of pre-term birth by 30 percent; use of a vaginal device to support the cervix or stitching the cervix shut until late pregnancy; visits to prematurity prevention clinics and weekly nurse contacts to check on expectant mothers’ symptoms; and baby aspirin to reduce inflammation.

Treatments to help babies who are born prematurely may include antibiotics, magnesium sulfate to reduce neurological disabilities and umbilical cord “milking” to push more oxygen-carrying red blood cells into premature babies just after delivery.

Women who are shown by the test to not be at high risk and those randomly assigned to the control group will receive normal obstetrical care, unless they later develop symptoms that require treatment for possible preterm birth at a high-risk obstetrics clinic.

The study design is adaptive, with readouts expected to occur sometime between 18 and 24 months.

If the study shows the PreTRM test and early intervention can reduce preterm births, the researchers hope to subsequently study whether that translates into fewer disabilities and lower healthcare expenses for premature babies.

“Every day a woman stays pregnant after 24 weeks saves $10,000 in the cost of taking care of the baby,” Dr. Branch said. “Each year in the United States, we spend tens of billions of dollars taking care babies who are born too early. That’s why this study is so important.”

###

More Info
February 12, 2018. Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology

 — Xpresys® Lung and PreTRM® Tests Featured as Demonstrating Pathway to Successful Development and Clinical Implementation —

Seattle, WA and Salt Lake City, February 12 – Sera Prognostics, a women’s health company, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, “The building blocks of successful translation of proteomics to the clinic,” by Leroy Hood and colleagues published online in Current Opinion in Biotechnology. The paper outlined six key strategies for successfully translating multiplexed tests using selective reaction monitoring (SRM-MS) mass spectrometry into clinical practice and highlighted strategies successfully utilized in the development of the only two multiplexed SRM-MS diagnostic tests currently used in clinical practice, Xpresys® Lung and PreTRM®. The paper will be printed in the June issue of Current Opinion in Biotechnology.

“This publication validates the use of a systems-biology approach as a valuable strategy for successfully developing multiplexed SRM-MS diagnostics, by helping to identify and prioritize relevant biomarkers and by informing discovery study design,” said Leroy Hood, MD, PhD, SVP and Chief Science Officer, Providence St. Joseph Health; Chief Strategy Officer, Co-founder and Professor, ISB. “This disease-agnostic technique holds value in supporting the development of proteomic tests across disease states and significantly advancing care for patients.”

Other strategies gleaned from the successful commercial development of Xpresys Lung and PreTRM are discussed in the paper. SRM-MS is highlighted as a superior diagnostic technology compared to currently used diagnostic methods due to its high specificity, high multiplexing capabilities and low assay development costs.

“The importance of highly multiplexed proteomics for understanding complex diseases and conditions, such as cancer and pregnancy, cannot be overstated. The general process described in this paper provides the blueprint for the successful development of proteomic solutions for a diverse range of clinically unmet challenges,” said Paul Kearney, Ph.D., President, Chief Science Officer and Co-Founder of Integrated Diagnostics.

“Together with Integrated Diagnostics and the Institute of Systems Biology, we are proud to have pioneered novel mass spectrometry proteomic diagnostic tests using rigorous systems-biology approaches,” said Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, Sera Prognostics. “SRM-MS is scalable and cost-effective, moving from a research tool into clinical production settings. This work offers a roadmap for developing future tests, enabling better diagnosis and stratification of patients according to disease sub-types, responses to therapy and potential outcomes. The technology holds great promise for meaningful advances in precision and personalized medicine in patients with conditions that have been traditionally very difficult to diagnose. PreTRM and Xpresys Lung are two examples of the kinds of new innovative tests made possible through careful scientific discovery and development.”

To view the full paper, click https://doi.org/10.1016/j.copbio.2017.12.011

About the PreTRM® Test

The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test is ordered by a medical professional. For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

About Institute for Systems Biology
The Institute for Systems Biology is a nonprofit biomedical research organization based in Seattle. It was founded in 2000 by systems biologist Leroy Hood, immunologist Alan Aderem, and protein chemist Reudi Aebersold. ISB was established on the belief that the conventional models for exploring and funding breakthrough science have not caught up with the real potential of what is possible today. ISB serves as the ultimate environment where scientific collaboration stretches across disciplines and across academic and industrial organizations, where our researchers have the intellectual freedom to challenge the status quo, and where grand visions for breakthroughs in human health inspire a collective drive to achieve the seemingly impossible. Our core values ensure that we always keep our focus on the big ideas that eventually will have the largest impact on human health. ISB is an affiliate of Providence St. Joseph Health, one of the largest not-for-profit health care systems in the United States.

About Indi

Indi (Integrated Diagnostics) is redefining molecular diagnostics and creating powerful new tools for physicians to non-invasively assess and more effectively manage complex diseases to improve patient outcomes, reduce complications, and lessen costs to the healthcare system. With the company’s first breakthrough test, Xpresys Lung, which measures multiple blood proteins and identifies lung nodules with a high probability of being benign, physicians have the potential to reduce risks and the need for unnecessary invasive procedures.

The company was co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, who in 2011 received the National Medal of Science from the U.S. government. His groundbreaking research is based on a systems biology approach, which measures hundreds of protein biomarkers found in blood to report on the physiological state of the body’s 50 major organs, such as the lungs.

Investors include Baird Capital, InterWest Partners, Life Sciences Alternative Financing and the Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com.

About Sera Prognostics, Inc.

Sera Prognostics is a global leader in high value women’s health diagnostics, delivering pivotal information to physicians to improve health and improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. The Company recently launched its first product, the PreTRM® test, nationwide through LabCorp’s expansive network of 1,750 patient service centers. PreTRM is the first and only broadly clinically-validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, the Bill & Melinda Gates Foundation, and LabCorp, the exclusive U.S. distributor of the PreTRM test. Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

More Info
June 23, 2017. Sera Prognostics Announces Analytical Validation Study

SALT LAKE CITY, June 26, 2017Sera Prognostics, Inc., a women’s healthcare company, announced today that its recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry.  The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers.  This work confirms Sera’s ability, across instrument generations, to perform accurate analytical measurements required to provide individualized determination of a woman’s risk of spontaneous early delivery through Sera’s groundbreaking PreTRM® test. The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.

“The Clinical Mass Spectrometry analytical validation paper highlights the strong science and rigorous analytical process discipline that underpins Sera’s commercial PreTRM® testing.  It further demonstrates the robustness of our LC/MS technology platform,” said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics.  “Sera’s high performing analytical platform accurately measures important biomarkers that are highly predictive of spontaneous premature delivery, a prerequisite for addressing the enormous global challenges of prematurity.”

About Preterm Birth

According to the March of Dimes, globally preterm birth affects 15 million infants each year, with 1 million deaths occurring from prematurity.  Of nearly 4 million babies born annually in the U.S., approximately one in ten is born prematurely. Preterm birth is defined as any birth before 37 weeks gestation, and is the leading cause of illness and death in newborns. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children.

About the PreTRM® Test

The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth.  The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test enables researchers to better understand the causes of preterm birth and to develop new therapies to improve newborn health.

The PreTRM test is ordered by a medical professional.

For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel.  You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.

Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM® test, the first and only broadly clinically-validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s technology addresses both the health and economic challenges of PTB. The Company’s strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, the Bill & Melinda Gates Foundation, and LabCorp, who recently entered into an agreement with the Company to become the exclusive U.S. distributor of the PreTRM test. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at  www.seraprognostics.com.

Company Contact:
Andrew Sauter, CFO                                  
Sera Prognostics, Inc.                                    
info@seraprognostics.com
(801) 990-0772

Media Contact for Sera Prognostics:
Terri Clevenger
Continuum Health Communications
tclevenger@continuumhealthcom.com
(203) 856-4326

More Info
May 23, 2017. LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth

The PreTRM Test is the Only Validated Test That Provides Early and Individualized Evaluation of Preterm Birth Risk

BURLINGTON, N.C. – May 23, 2017 – LabCorp® (NYSE: LH) today announced the nationwide availability the PreTRM® test.  Developed by Sera Prognostics, Inc., the PreTRM test is the first of its kind validated blood test that provides an early and individualized prediction of preterm birth risk for pregnant women. LabCorp and Sera previously announced their strategic collaboration for LabCorp to be the exclusive U.S. distributor of Sera’s PreTRM test. LabCorp was also a lead investor in Sera’s recently closed Series C financing round.

“As the exclusive U.S. laboratory to offer Sera’s PreTRM test, LabCorp continues to build a leading position in women’s and reproductive health diagnostics,” said Gary M. Huff, chief executive officer of LabCorp Diagnostics. “We are excited about our collaboration with Sera, and this innovative test is part of our ongoing strategy to deliver world-class diagnostics that can improve health and lives.”

The PreTRM test is performed on a standard blood specimen collected during weeks 19 and 20 of pregnancy. The specimen must be collected at one of LabCorp’s over 1,750 patient service centers.

The test can help physicians provide better care by helping to predict the risk of preterm birth, providing the opportunity to intervene earlier to help extend the pregnancy towards full-term. Preterm birth is the leading cause of infant mortality and morbidity in the U.S. and worldwide. Approximately 400,000 of the 4,000,000 annual births in the U.S. are preterm, defined as prior to week 37 of pregnancy, and up to 50 percent of women who delivery prematurely do not have any identified risk factors for preterm birth. According to the March of Dimes, the average cost of care for a premature baby is ten times the average cost for a full-term baby. Children born prematurely can require long-term or lifetime care, with significant additional cost. Each additional week towards full-term pregnancy can help to prevent mortality, improve a variety of health outcomes, including respiratory and neurodevelopmental outcomes, and eliminate or reduce the expense and impact of caring for a preterm infant.

The PreTRM test was supported by the landmark Proteomic Assessment of Preterm Risk study, which followed over 5,500 pregnant women, analyzed over 300 proteins in maternal blood and identified a two-protein signature that was found to be highly predictive of spontaneous preterm birth. The test is a significant addition to LabCorp’s differentiated women’s healthcare and reproductive genetics offerings. These include MaterniT®21, a proprietary, clinically validated non-invasive prenatal test, and the industry’s largest network of genetic counselors who can help patients understand genetic test results. In addition, LabCorp offers patient-focused services such as support to obtain insurance pre-authorization before a test is performed and a personalized estimate of the out-of-pocket cost of services before specimen collection by LabCorp.

For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel. You can also join the conversation on Facebook and @PreTRM. For more information about LabCorp’s comprehensive pregnancy services from preconception through delivery, including the PreTRM test, please visit www.labcorp.com/provider-services/programs/partners-pregnancy

About the PreTRM Test

The PreTRM test is the first of its kind validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test enables researchers to better understand the causes of preterm birth and to develop new therapies to improve newborn health. The PreTRM test is ordered by a medical professional.                                                                                                                                    

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016 through the contributions of 52,000 employees in approximately 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

This press release contains forward-looking statements including with respect to estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers.  Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

More Info
January 10, 2017. Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® Test

 

SALT LAKE CITY, January 10, 2017LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth

Sera Prognostics, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test. PreTRM is the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.

In addition, LabCorp will lead Sera’s $40 million Series C financing. Proceeds from the Series C financing, which includes existing investors, enable Sera to continue building clinical evidence to support reimbursement and insurance coverage decisions, as well as expand commercialization nationwide for the PreTRM test. Sera plans to leverage LabCorp’s market leading position in NIPT, women’s healthcare and reproductive genetics and its nationwide network of 1,750 patient service centers to make PreTRM broadly accessible to physicians and patients concerned about preterm birth risk.

“We are very excited to enter into this collaboration with LabCorp to expand our reach in the maternal fetal medicine community, enabling us to further educate both physicians and patients on the value of knowing the risk, early in pregnancy, of premature birth,” said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics. “As highlighted by two recent publications, experts state that use of biomarker testing is ‘a dominant strategy’ for addressing the negative impact of prematurity. We are confident that with this financing and collaboration, Sera can realize its vision of improving neonatal health and associated economics in the U.S. and worldwide.”

Sera initiated a targeted launch of PreTRM with limited commercial access in select geographies in 2016 and will expand the test’s availability nationwide in 2017 in partnership with LabCorp.

“Sera’s PreTRM test is a unique offering and one that has the potential to change the way prematurity is identified and treated today,” said David P. King, chairman and chief executive officer of LabCorp. “The collaboration with Sera expands our ability to provide patients and physicians with one source for the most complete range of testing options in women’s health, in support of our mission to improve health and improve lives.”

“As a market leader in NIPT, women’s health and reproductive genetics, LabCorp brings a significant depth of experience that will help expand the commercialization of PreTRM. Together, we are working toward reducing the social and economic burden of prematurity by more accurately predicting preterm birth risk and providing both physicians and patients the opportunity to intervene earlier to address prematurity risk, with the goal of improving the lives of women and their babies,” said Dr. Critchfield.

About Preterm Birth

According to the March of Dimes, globally preterm birth affects 15 million infants each year, with 1 million deaths occurring from prematurity. Of nearly 4 million babies born annually in the U.S., approximately one in ten is born prematurely. Preterm birth is defined as any birth before 37 weeks gestation, and is the leading cause of illness and death in newborns. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children.

About the PreTRM® Test

The PreTRM® test is the first and only clinically validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM test enables researchers to better understand the causes of preterm birth and to develop new therapies to improve newborn health.

The PreTRM test is ordered by a medical professional.

For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.

Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM® test, the first and only clinically validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s technology addresses both the health and economic challenges of PTB. The Company’s strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, and the Bill & Melinda Gates Foundation. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

Company Contact:

Andrew Sauter, CFO
Sera Prognostics, Inc.
info@seraprognostics.com
(801) 990-0772

Media Contact for Sera Prognostics:

Terri Clevenger
Continuum Health Communications
tclevenger@continuumhealthcom.com
(203) 856-4326

More Info
December 19, 2016. Two Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® Test

Experts Predict a Reduction of Infant Mortality by 23.5% and Annual Direct Medical Costs of More Than $500 million Through Preterm Birth Risk Testing 

SALT LAKE CITY, December 19, 2016 – Sera Prognostics, Inc., a women’s healthcare company, today announced the recent publications of two reports showing significant clinical utility of assessing preterm birth risk early in pregnancy with novel biomarker tests.  These reports describe treatment paradigms that use existing interventions with significant potential to improve the health of premature babies, including reduction in mortality rates, as well as a corresponding reduction of direct medical costs to the health care system.

“These important publications analyze better ways to address the severe health and economic impact of prematurity on US families,” stated Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics, “and demonstrate the value of knowing early in pregnancy a woman’s risk for premature delivery.  By using interventions earlier, physicians can seek to prolong pregnancies as a strategy to improve the chances of healthier babies.  Sera is proud to offer the PreTRM® test, the only clinically validated blood test for the early prediction of preterm birth risk, as we work to make the company’s vision a reality:  To improve the health of women and infants and decrease the costs of healthcare worldwide.”

A comprehensive analysis conducted by a group of noted health economists entitled,

Clinical and Cost Impact Analysis of a Novel Prognostic Test for Early Detection of Preterm Birth, was published in the American Journal of Perinatology Reports, and available at https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0036-1593866.pdf .  The authors concluded that “the use of a prognostic test for reducing spontaneous preterm birth is a dominant strategy that could reduce costs and improve outcomes.”  Other findings from the report state that preterm birth risk testing and intervention could result in:

  • 23.5% reduction in infant mortality (approximately 2,000 fewer neonatal deaths per year)
  • 27.7% reduction in acute conditions at birth
  • 23,430 fewer preterm births per year
  • $511 million reduction in direct medical costs to the US healthcare system from preterm infants in the first year of life

“The clinical and financial impact of preterm birth continues to increase and contribute to the rising cost of healthcare in the US,” said Jay D. Iams, MD, Emeritus Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.  “The outcome of our in-depth analysis showed the potential significance of a novel prognostic test such as PreTRM®, to improve neonatal health and achieve subsequent reduction of overall costs of preterm birth on the healthcare system.”

A separate article entitled Preterm Birth: can we do better? was published in Proceedings in Obstetrics and Gynecology, and is available at http://ir.uiowa.edu/cgi/viewcontent.cgi?article=1307&context=pog.  The authors present a clinical treatment protocol for testing women early in pregnancy with a validated biomarker test for preterm birth risk, and administering recommended interventions based on a woman’s individual risk.  The paper discusses:

  • The clear need to validate biomarkers that provide quantitative, individualized assessment of risk early in pregnancy.
  • That physicians must increase efforts to optimize current treatments and invest in the development of new interventions and focus on incremental improvements in neonatal health and cost reduction.
  • Beneficial interventions for high risk women that include screening and treatment for cervical shortening or infection, referrals to maternal-fetal specialists, progesterone therapies, and other treatments such as tocolysis and steroids.

Scott A. Sullivan, MD, MSCR, Professor and Division Director of Maternal-Fetal Medicine at the Medical University of South Carolina, stated “For the first time, our team of experts have recommended a treatment algorithm that suggests increased use of a range of interventions, based on a woman’s individual risk prediction from a validated biomarker test, now available, that all doctors can follow with the goal of improving neonatal outcomes.”

About Preterm Birth

According to the March of Dimes, globally preterm birth affects 15 million infants each year, with 1 million deaths occurring from prematurity.  Of the 4 million babies born annually in the U.S., approximately one in ten is born prematurely. Preterm birth is defined as any birth before 37 weeks gestation, and is the leading cause of illness and death in newborns. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children.

About the PreTRM® Test

The PreTRM® test is the first and only clinically validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. Using proteomic technology, the PreTRM® test measures and analyzes proteins in the blood that are highly predictive of preterm birth.  The PreTRM® test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM® test enables researchers to better understand the causes of preterm birth and to develop new therapies to improve newborn health.

The PreTRM® test is ordered by a medical professional.

For more information about the PreTRM® test, please visit www.PreTRM.com and the PreTRM® test YouTube Channel.  You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.

Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM® test, the first and only clinically validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s proprietary technology addresses both the health and economic challenges of PTB. The Company’s strong management team has significant clinical development and women’s healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, and the Bill & Melinda Gates Foundation. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally.  Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

Company Contact:                                        
Andrew Sauter, CFO                                     
Sera Prognostics, Inc.                                 
info@seraprognostics.com
(801) 990-0772

Media Contact for Sera Prognostics
Terri Clevenger
Continuum Health Communications
tclevenger@continuumhealthcom.com
(203) 856-4326

More Info
May 12, 2016. Sera Prognostics’ PreTRM® Test Wins 2016 Utah Innovation Award in Life Sciences

First-in-Class Novel Commercial Blood Test to Predict Early, Accurate, Individualized Risk for Premature Birth

SALT LAKE CITY, May 12, 2016 — Sera Prognostics, Inc., a women’s health company, today announced that it was selected as the 2016 Utah Innovation Award winner in the Life Science – BioTech category for its novel PreTRM® test, a clinical blood test for early, individualized risk assessment of premature birth. The winners were announced at the 14th annual Utah Innovation Awards presented by Stoel Rives, LLP and the Utah Technology Council held on May 11, 2016, at the Hilton Salt Lake City Center.

The PreTRM test, now commercially available nationwide, is the first and only clinically validated blood test of its kind, based on a large prospective clinical study that is representative of single birth pregnancies occurring in the U.S.

“It is an honor for Sera’s talented team to be recognized along with this year’s other companies that exemplify the entrepreneurial spirit of Utah,” stated Gregory C. Critchfield, M.D. chairman and CEO of Sera Prognostics. “Sera is focused on addressing the enormous economic and healthcare burden that premature birth places on infants, their families and society. Until now, physicians have had few options to identify women who are at increased risk of premature birth, as evidenced by the fact that approximately 50 percent of premature deliveries occur in women with no known risk factors. The innovative research behind the PreTRM test has helped us create an early, accurate and individualized assessment tool that enables physicians to make more informed decisions with their patients in managing the risks of women who need greater attention. We believe that this technology will not only benefit newborn health in the U.S., but also will have a substantial impact in reducing the frequency and severity of prematurity worldwide.”

Premature birth, defined as birth before 37 weeks, occurs globally in 15 million pregnancies each year, with one million deaths occurring from complications. According to the Centers for Disease Control and the March of Dimes, each year in the United States, approximately one in ten babies are born too early. Preterm birth is the leading cause of illness and death in newborns and is associated with significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss. The costs of treating complications of premature birth in the U.S. were greater than $26 billion in 2005, according to the March of Dimes, with current costs estimated to be much higher. The burden of prematurity is even more severe in low income countries. Sera is working with the Bill & Melinda Gates Foundation to develop technologies that can benefit the health of women and their infants in underserved regions of the world.

The annual Utah Innovation Awards is a statewide program designed to recognize innovations and the Utah companies that created them. The competition involved more than 100 companies in technology and life sciences. More than 80 experts representing Utah’s private industry, government and academic communities reviewed the selections and voted on winners and finalists in each category.

“Sera Prognostics is a great example of the scientific innovation happening in Salt Lake City and other parts of Utah,” stated R. Whitney Johnson, Partner at Stoel Rives. “With its advanced research techniques and robust strategy, Sera developed the PreTRM test to address the severe consequences of prematurity and is now poised to help physicians reduce the impact of preterm birth for mothers and their babies.”

About the PreTRM® Test
The PreTRM test is an innovative new blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM test can help physicians identify early in the pregnancy (during weeks 19 and 20 of gestation) which women are at increased risk for premature delivery, enabling more informed management decisions based on each women’s individual risk. Using proteomic technology, the PreTRM test measures and analyzes proteins in the blood that are predictive of preterm birth. Better understanding of the proteins expressed in pregnancy may lead to understanding the causes of preterm birth and making further advancements in prolonging gestational age and improving newborn outcomes.

For more information about the PreTRM® test, please visit www.PreTRM.com and the PreTRM test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.
Sera Prognostics is a private biotechnology company developing innovative diagnostic tests for the early prediction of preterm birth risk and other pregnancy complications. Sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. The Company has assembled a strong management team and Board of Directors with significant clinical development and women’s healthcare diagnostic experience. The Company is supported by a strong group of investors, including the Bill & Melinda Gates Foundation, Chione, Ltd, Domain Associates, InterWest Partners, Catalyst Health Ventures, UpStart Life Sciences Capital, and Osage University Partners. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

Company Contact:
Andrew Sauter, CFO
Sera Prognostics, Inc.
info@seraprognostics.com
(801) 990-0772

Media Contact for Sera Prognostics
Terri Clevenger
Continuum Health Communications
tclevenger@continuumhealthcom.com
(203) 856-4326

 

More Info